Docon Applied sciences Pvt Ltd, a promoter entity of Thyrocare Applied sciences Ltd., has offloaded about 53.33 lakh shares, representing practically 10% of the diagnostics firm’s whole paid-up capital, by open-market transactions on October 24.

The sale, valued at Rs 667.7 crore at a mean value of Rs 1,252 per share, trimmed Docon’s stake in Thyrocare from 71% to 61%, in response to a stock-exchange submitting.

The promoter group continues to carry round 3.2 crore shares, sustaining its controlling curiosity within the firm.

The block deal attracted robust curiosity from home institutional traders. ICICI Prudential Mutual Fund acquired 17.49 lakh shares price Rs 218.9 crore, whereas Aditya Birla Solar Life Mutual Fund picked up 10.33 lakh shares for Rs 129.3 crore. Different consumers included HSBC Mutual Fund Midcap Fund (6.66 lakh shares; Rs 83.4 crore), HDFC Mutual Fund (4.44 lakh shares; Rs 55.5 crore), and Eastspring Investments India Client Fairness Open Restricted (3.19 lakh shares; Rs 40 crore).

Following the stake sale, Docon mentioned in an change submitting that its shareholding now stands at 60.93%, down from 70.98% earlier than the transaction. Shares of Thyrocare closed 1.99% greater at Rs 1,269.70 on the NSE.

Thyrocare just lately reported a sturdy second-quarter efficiency for FY26. Income from operations rose 22% year-on-year to Rs 216.5 crore, up from Rs 177.36 crore in Q2 FY25. Internet revenue surged 81% YoY to Rs 47.9 crore, in contrast with Rs 26.4 crore in the identical interval final yr. For the primary half of FY26, web revenue climbed 71% to Rs 86.1 crore.